Please note that due to a high volume of submissions, the ANZCTR is currently experiencing a delay in processing of submissions and updates.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
A phase II trial of adjuvant chemo-radiation followed by chemotherapy for patients with newly diagnosed endometrial carcinoma at high-risk of relapse
Scientific title
A phase II trial to evaluate the effect on progression-free survival of adjuvant chemo-radiation followed by chemotherapy with carboplatin and paclitaxel for patients with newly diagnosed endometrial carcinoma at high-risk of relapse
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Endometrial carcinoma 687 0
Condition category
Condition code
Cancer 761 761 0 0
Womb (Uterine or endometrial cancer)

Study type
Description of intervention(s) / exposure
Adjuvant chemo-radiation followed by chemotherapy. Patients will be treated with adjuvant pelvic radiotherapy plus concurrent Carboplatin chemotherapy, followed by 4 cycles of chemotherapy with Carboplatin plus Paclitaxel. The toal duration of the intervention is 24 weeks.
Intervention code [1] 673 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 965 0
Progression-free survival
Timepoint [1] 965 0
All patients will be followed and reported on for 5 years.
Secondary outcome [1] 1830 0
To determine time to local failure
Timepoint [1] 1830 0
Secondary outcome [2] 1831 0
Duration of local control
Timepoint [2] 1831 0
Secondary outcome [3] 1832 0
Overall survival
Timepoint [3] 1832 0
Secondary outcome [4] 1833 0
To document the acute and long-term toxicities of the adjuvant treatment as well as patterns of disease recurrence.
Timepoint [4] 1833 0

Key inclusion criteria
Patients must have newly diagnosed, histologically confirmed endometrial carcinoma, and have undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy with or without a dissection of pelvic and/or para-aortic nodes. It is also recommended that patients will have undergone an omentectomy and had peritoneal washings taken. In addition, patients must be either:A. Patients with documented involvement of pelvic and/or para-aortic nodes by histology (FIGO stage IIIc) or post-operative PET, CT or PET/CTORB. Patients who have not undergone a complete lymphadenectomy, who have negative sampled nodes or unknown nodal status and have high-risk disease as defined by:a) FIGO stage Ic or IIb with : aggressive non-endometroid histology (serous papillary or clear cell type comprising 10% of the endometrial tumour) ORb) FIGO stage IIb with : grade 3 histologyc) Any FIGO stage III disease excluding those defined as stage III only by positive peritoneal cytologyPatients must not have received any prior chemotherapy for another malignancy. Patients who have been treated for other malignancies must not have received prior pelvic or abdominal radiotherapy, and any prior radiotherapy must have been to less than 15% of the bone marrow bearing areasECOG performance status less than 2Life expectancy of greater than 6 months.Patients must have normal organ and marrow function as defined below:- absolute neutrophil count >1,500- platelets > 100,000- total bilirubin < 1.25 X upper limit of normal - AST(SGOT)/ALT(SGPT) <3 X institutional upper limit of normal.- estimated GFR > 50 ml/minPatient has given written informed consent.
Minimum age
Not stated
Maximum age
Not stated
Can healthy volunteers participate?
Key exclusion criteria
Patients with other invasive malignancies, with the exception of treated non-melanoma skin cancer, in the last 5 yearsPatients receiving any other therapeutic investigational agents Patients who are receiving concurrent treatment with any other anti-cancer therapyPatients who have commenced any post-surgical anti-cancer treatment for endometrial cancerEvidence of distant metastasesHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel or carboplatin Symptomatic peripheral neuropathy greater than or equal to grade 2.Serious illness of medical condition that precludes the safe administration of the trial treatment including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase II multi-centre trial
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 842 0
Commercial sector/Industry
Name [1] 842 0
Bristol-Myers Squibb
Address [1] 842 0
Country [1] 842 0
United States of America
Primary sponsor type
Peter MacCallum Cancer Centre
Secondary sponsor category [1] 709 0
Name [1] 709 0
Address [1] 709 0
Country [1] 709 0

Ethics approval
Ethics application status
Ethics committee name [1] 2109 0
Peter MacCallum Cancer Centre
Ethics committee address [1] 2109 0
Ethics committee country [1] 2109 0
Date submitted for ethics approval [1] 2109 0
Approval date [1] 2109 0
Ethics approval number [1] 2109 0

Brief summary
This is a trial of follow-up (adjuvant) treatment with combined chemotherapy and radiation treatment followed by further chemotherapy for women who have undergone surgery for endometrial carcinoma but are thought to be at high-risk of developing relapse of the cancer
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 35663 0
Address 35663 0
Country 35663 0
Phone 35663 0
Fax 35663 0
Email 35663 0
Contact person for public queries
Name 9862 0
Hannah O'Leary
Address 9862 0
Research Nurse
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Country 9862 0
Phone 9862 0
+61 3 96561111
Fax 9862 0
+61 3 96561408
Email 9862 0
Contact person for scientific queries
Name 790 0
Dr Linda Mileshkin
Address 790 0
Peter MacCallum Cancer Centre
St Andrews Place
East Melbourne VIC 3002
Country 790 0
Phone 790 0
+61 3 96561697
Fax 790 0
+61 3 96561408
Email 790 0

No information has been provided regarding IPD availability
Summary results
No Results